Results 201 to 210 of about 40,867 (262)

Tuberculous lymphadenitis presenting with hypercalcemia and acute kidney injury: Diagnostic challenges and management insights: A case report. [PDF]

Radiol Case Rep
Gupta S, Malde S, Kashiv P, Dubey S, Pawar T, Jeyachandran V, Kurundwadkar M, Sejpal K, Bawankule C, Pasari A, Balwani M.   +10 more
europepmc   +1 more source

Adherence to denosumab therapy and all-cause mortality in dialysis patients with osteoporosis: a retrospective cohort exploratory study. [PDF]

Front Pharmacol
Chen YC, Chen JF, Yu SF, Hsu CY, Chiu CH.   +4 more
europepmc   +1 more source

Assessment of the efficacy and safety of anti-sclerostin antibody therapy for osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Front Endocrinol (Lausanne)
Chen L, Wang Q, Gu M.
europepmc   +1 more source

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial [PDF]

core   +1 more source

Histomorphologic Assessment of Osteoregeneration in a Rabbit Femur Model With Xenograft, Bone Morphogenetic Protein-2, Platelet-Rich Plasma, and Denosumab. [PDF]

Plast Reconstr Surg Glob Open
Tuleubayev B, Kamyshanskiy Y, Kurmangaliyev YD, Koshanova A, Avromidi I, Kossilova Y, Darybayev D.   +6 more
europepmc   +1 more source

Successful management of denosumab discontinuation in a patient with primary pediatric osteoporosis. [PDF]

Bone Rep
Anastasilakis AD, Makras P, Polyzos SA, Yavropoulou MP, Papapoulos SE.   +4 more
europepmc   +1 more source

The Role of HER2 and RANK in Breast Cancer and New Therapeutic Approaches With Denosumab, Anti-HER2 Antibodies and Immunotherapy. [PDF]

J Cell Mol Med
Sarantis P, Simatou A, Anastasiou IA, Palamaris K, Trifylli EM, Koustas E, Piperi C, Karamouzis MV, Papavassiliou AG.   +8 more
europepmc   +1 more source

What's new on giant cell tumor of bone. [PDF]

SICOT J
Tsukamoto S, Errani C, Balach T, Zamora T, Ortiz-Cruz E, Rajasekaran RB, Yau R, Ji T, Pérez-Muñoz I, Linares F, Angelini A, Ruggieri P, Benevenia J, Mavrogenis AF.   +13 more
europepmc   +1 more source

A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children's Oncology Group. [PDF]

Clin Cancer Res
Janeway KA, Chou AJ, Buxton A, Reid J, Isakoff MS, Kopp L, Hingorani P, Lee JL, Doski J, Daldrup-Link H, Hall L, Randall RL, Reed DR, Dubois SG, Krailo M, Grier H, Gorlick R.   +16 more
europepmc   +1 more source